OTC Markets OTCPK - Delayed Quote USD

Endonovo Therapeutics, Inc. (ENDV)

0.0003
0.0000
(0.00%)
As of April 22 at 4:00:00 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
16.0250
140.2420
135.3550
73.1050
165.7960
Cost of Revenue
9.7260
7.8400
9.9900
14.9850
65.3690
Gross Profit
6.3000
132.4020
125.3650
58.1200
100.4270
Operating Expense
1,992.1240
3,051.8460
3,389.7050
2,284.6670
3,012.6250
Operating Income
-1,985.8240
-2,919.4440
-3,264.3400
-2,226.5470
-2,912.1980
Net Non Operating Interest Income Expense
-1,302.1780
-1,282.2960
-1,321.5750
-941.5660
-2,083.0740
Other Income Expense
--
11,126.3340
-13,888.9200
63.2190
4,599.6880
Pretax Income
-3,731.1980
6,924.5940
-18,474.8350
-3,104.8940
-395.5840
Net Income Common Stockholders
-3,731.1980
6,924.5940
-18,474.8350
-3,104.8940
-395.5840
Diluted NI Available to Com Stockholders
-3,731.1980
6,924.5940
-18,474.8350
-3,104.8940
-395.5840
Basic EPS
-0.00
0.03
-0.13
-0.05
-0.03
Diluted EPS
-0.00
0.01
-0.13
-0.05
-0.03
Basic Average Shares
414,808.8200
276,355.1560
139,206.5110
59,836.6200
12,215.8440
Diluted Average Shares
1,489,222.0060
1,350,768.3420
139,206.5110
59,836.6200
12,215.8440
Total Operating Income as Reported
-1,985.8250
-2,919.4440
-3,264.3400
-2,226.5470
-2,912.1980
Total Expenses
2,001.8500
3,059.6860
3,399.6950
2,299.6520
3,077.9940
Net Income from Continuing & Discontinued Operation
-3,731.1980
6,924.5940
-18,474.8350
-3,104.8940
-395.5840
Normalized Income
-3,288.0030
-4,233.7390
-4,811.1830
-3,168.1130
-5,447.3670
Interest Expense
1,302.1780
1,282.2960
1,321.5750
941.5660
2,083.0740
Net Interest Income
-1,302.1780
-1,282.2960
-1,321.5750
-941.5660
-2,083.0740
EBIT
-2,429.0200
8,206.8900
-17,153.2600
-2,163.3280
1,687.4900
EBITDA
-1,782.1090
8,853.8020
-16,506.3480
-1,514.8360
2,338.7370
Reconciled Cost of Revenue
9.7260
7.8400
9.9900
14.9850
65.3690
Reconciled Depreciation
646.9110
646.9120
646.9120
648.4920
651.2470
Net Income from Continuing Operation Net Minority Interest
-3,731.1980
6,924.5940
-18,474.8350
-3,104.8940
-395.5840
Total Unusual Items Excluding Goodwill
-443.1950
11,158.3330
-13,663.6520
63.2190
5,051.7830
Total Unusual Items
-443.1950
11,158.3330
-13,663.6520
63.2190
5,051.7830
Normalized EBITDA
-1,338.9140
-2,304.5310
-2,842.6960
-1,578.0550
-2,713.0460
12/31/2020 - 11/15/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CNBX CNBX Pharmaceuticals Inc.
0.0100
+143.90%
 
GON.DU Geron Corp
1.1400
-0.18%
 
BT3.BE Lineage Cell Therapeutics Inc
0.3720
+10.71%
 
HTD.MU Corcept Therapeutics Inc
56.94
+3.98%
 
0M4.DU Mersana Therapeutics Inc
0.3341
+3.63%
 
RASP Actavia Life Sciences, Inc.
0.0040
0.00%
 
300759.SZ Pharmaron Beijing Co., Ltd.
22.72
+2.25%
 
PI3.DU Gubra AS
48.22
+4.64%
 
PL3.F TuHURA Biosciences, Inc.
3.5800
+2.29%
 
50BA.F Bicycle Therapeutics plc
7.60
+16.92%